- Home
- UCAR vs LPTX Comparison
UCAR vs LPTX Comparison
Compare UCAR & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UCAR
- LPTX
- Stock Information
- Founded
- UCAR 2013
- LPTX 2011
- Country
- UCAR China
- LPTX United States
- Employees
- UCAR N/A
- LPTX N/A
- Industry
- UCAR Retail-Auto Dealers and Gas Stations
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- UCAR Consumer Discretionary
- LPTX Health Care
- Exchange
- UCAR Nasdaq
- LPTX Nasdaq
- Market Cap
- UCAR 10.1M
- LPTX 11.1M
- IPO Year
- UCAR 2023
- LPTX N/A
- Fundamental
- Price
- UCAR N/A
- LPTX $0.62
- Analyst Decision
- UCAR Strong Buy
- LPTX Hold
- Analyst Count
- UCAR 1
- LPTX 1
- Target Price
- UCAR $5.00
- LPTX N/A
- AVG Volume (30 Days)
- UCAR 129.2K
- LPTX 7.8M
- Earning Date
- UCAR 05-15-2026
- LPTX 11-12-2025
- Dividend Yield
- UCAR N/A
- LPTX N/A
- EPS Growth
- UCAR N/A
- LPTX N/A
- EPS
- UCAR N/A
- LPTX N/A
- Revenue
- UCAR $6,816,075.00
- LPTX N/A
- Revenue This Year
- UCAR N/A
- LPTX N/A
- Revenue Next Year
- UCAR N/A
- LPTX N/A
- P/E Ratio
- UCAR N/A
- LPTX N/A
- Revenue Growth
- UCAR 57.22
- LPTX N/A
- 52 Week Low
- UCAR $1.74
- LPTX $0.22
- 52 Week High
- UCAR $9.43
- LPTX $4.79
- Technical
- Relative Strength Index (RSI)
- UCAR 41.04
- LPTX 58.49
- Support Level
- UCAR $1.93
- LPTX $0.62
- Resistance Level
- UCAR $2.12
- LPTX $0.78
- Average True Range (ATR)
- UCAR 0.10
- LPTX 0.13
- MACD
- UCAR 0.01
- LPTX 0.01
- Stochastic Oscillator
- UCAR 36.04
- LPTX 45.93
About UCAR U Power Limited
U Power Ltd is involved in the provision of vehicle sourcing services. It is principally engaged in the provision of new energy vehicles development and sales; battery swapping stations manufacturing and sales; battery swapping services, and sourcing services. The company, as a broker, engaged in sales of vehicles between automobile wholesalers and buyers, including small and medium-sized vehicle dealers and individual customers located in lower-tier cities in China.
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.